Section of Sport Science, Department of Public Health, Aarhus University, Aarhus, Denmark.
REVAL, BIOMED-Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
J Neurol Sci. 2017 Nov 15;382:131-136. doi: 10.1016/j.jns.2017.09.049. Epub 2017 Oct 3.
The severity of walking impairment in persons with multiple sclerosis (pwMS) at different levels on the expanded disability status scale (EDSS) is unclear. Furthermore, it is unclear if the EDSS is differently related to performed- and perceived walking capacity tests.
To quantify walking impairment and perceived impact of MS on walking according to EDSS scores and to examine the relations between these parameters in pwMS.
EDSS was collected by neurologists and walking was assessed by the timed 25ft walk test (T25FWT), two minute walk test (2MWT), six minute walk test (6MWT) and the 12-item MS walking scale (MSWS-12) in 474 PwMS with mild (EDSS 1-4: n=200) to moderate (EDSS 4.5-6.5: n=274) MS. Magnitude of walking impairment was calculated and related to EDSS.
Compared to predicted values in healthy controls, walking speed was reduced by 41.5±25.8% in the 6MWT for the total MS group and by 21.8±20.2% and 55.8±19.1% in the mild and moderate MS subgroups, respectively. The EDSS score showed the strongest relationship to the 2MWT and the 6MWT in the total MS group (r=-0.76, p<0.0001), to the MSWS-12 score in the mild MS group (r=0.56, p<0.0001), and to the 2MWT in the moderate MS group (r=-0.50, p<0.0001).
In pwMS (EDSS scores 1-6.5), walking speed is on average reduced by ~40% when compared to predicted values in healthy controls, and impairments are already present at early disease stages, suggesting early initiation of rehabilitation. The 2MWT and 6MWT show the strongest relationship to EDSS, but the MSWS-12 identify impairments more gradually at low EDSS scores.
多发性硬化症(pwMS)患者在扩展残疾状况量表(EDSS)的不同级别下行走障碍的严重程度尚不清楚。此外,EDSS 是否与实际和感知的步行能力测试有不同的相关性也不清楚。
根据 EDSS 评分量化 pwMS 的步行障碍和感知到的 MS 对步行的影响,并检查这些参数在 pwMS 中的相关性。
EDSS 由神经科医生收集,步行能力通过定时 25 英尺步行测试(T25FWT)、两分钟步行测试(2MWT)、六分钟步行测试(6MWT)和 12 项多发性硬化症步行量表(MSWS-12)评估。474 名 pwMS 患者中轻度(EDSS 1-4:n=200)至中度(EDSS 4.5-6.5:n=274)MS 患者的 EDSS 进行了评估。计算了行走障碍的程度,并与 EDSS 相关。
与健康对照组的预测值相比,总 MS 组的 6MWT 行走速度降低了 41.5%±25.8%,轻度 MS 组和中度 MS 组分别降低了 21.8%±20.2%和 55.8%±19.1%。EDSS 评分与总 MS 组的 2MWT 和 6MWT 相关性最强(r=-0.76,p<0.0001),与轻度 MS 组的 MSWS-12 评分相关性最强(r=0.56,p<0.0001),与中度 MS 组的 2MWT 相关性最强(r=-0.50,p<0.0001)。
在 pwMS(EDSS 评分 1-6.5)中,与健康对照组的预测值相比,行走速度平均降低了约 40%,并且在疾病早期阶段就已经存在障碍,这表明应尽早开始康复治疗。2MWT 和 6MWT 与 EDSS 的相关性最强,但 MSWS-12 在 EDSS 评分较低时更能逐渐识别障碍。